Scitara Corporation – Trademark Portfolio
Entity Type: 03
Scitara Corporation holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 10 filings in this category. The portfolio also extends into Class 38 (Telecommunications) across 3 Nice Classification classes. Currently, 8 trademarks are registered and 1 is pending. Notable registered marks include DLX, SIP, SCITARA, IPAAS FOR SCIENCE, and MEET THE MODERN LAB. The owner is based in Marlborough, MA.
11 Apex Drive Suite 300A
Marlborough, MA 01752
Showing of trademarks Trademarks
Trademark Classifications
Scitara Corporation's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Scitara Corporation have?
Scitara Corporation has 10 U.S. trademarks filed with the USPTO. Of these, 8 registered, 1 pending, 1 abandoned.
What trademark classes does Scitara Corporation file in?
Scitara Corporation files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 38 (Telecommunications), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Scitara Corporation's most well-known trademarks?
Scitara Corporation's registered trademark portfolio includes well-known marks such as DLX, SIP, SCITARA, IPAAS FOR SCIENCE, and MEET THE MODERN LAB. These are among 8 currently registered trademarks in the portfolio.
What is Scitara Corporation's trademark registration success rate?
Scitara Corporation has a 89% trademark registration rate, with 8 out of 9 resolved applications resulting in successful registration. Currently, 1 application is pending review.